The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.